{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:44:01Z","timestamp":1780371841849,"version":"3.54.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Rationale<\/jats:title><jats:p>Perifolliculitis capitis abscedens et suffodiens (PCAS), also known as dissecting cellulitis of the scalp (DCS), is a part of the \u201cfollicular occlusion tetrad\u201d that also includes acne conglobate (AC), hidradenitis suppurativa (HS), and pilonidal sinus, which share the same pathogenic mechanism, such as follicular occlusions, follicular ruptures, and follicular infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patient concerns<\/jats:title><jats:p>A 15-year-old boy had multiple rashes on the scalp accompanied by pain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>The patient was diagnosed with PCAS or DCS based on the clinical manifestations and laboratory examinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>The patient was initially administered adalimumab 40\u2009mg biweekly and oral isotretinoin 30\u2009mg daily for 5\u2009months. Because the initial results were insufficient, the interval between adalimumab injections was extended to 4\u2009weeks, and isotretinoin was changed to baricitinib 4\u2009mg daily for 2\u2009months. When the condition became more stable, adalimumab 40\u2009mg and baricitinib 4\u2009mg were administered every 20 and 3\u2009days, respectively, for two more months until now.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcomes<\/jats:title><jats:p>After 9\u2009months of treatment and follow-up, the original skin lesions of the patient were almost cured, and most inflammatory alopecia patches disappeared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our literature review did not find any previous reports on treating PCAS with TNF-\u03b1 inhibitors and baricitinib. Accordingly, we presented the first successful treatment of PCAS with this regimen.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1132574","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T04:39:53Z","timestamp":1679978393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review"],"prefix":"10.3389","volume":"10","author":[{"given":"Yuanting","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000242207","article-title":"Dermatitis follicularis et perifollicularis conglobata","volume":"10","author":"Spitzer","year":"1903","journal-title":"Dermatology"},{"key":"ref2","first-page":"567","article-title":"Pilonidal disease: origin from follicles of hairs and results of follicle removal as treatment","volume":"87","author":"Bascom","year":"1980","journal-title":"Surgery"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjd.13999","article-title":"Dissecting cellulitis of the scalp: a retrospective study of 51 patients and review of literature","volume":"174","author":"Badaoui","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1080\/09546634.2019.1642441","article-title":"Approach to treatment of refractory dissecting cellulitis of the scalp: a systematic review","volume":"32","author":"Thomas","year":"2021","journal-title":"J Dermatol Treat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e15763","DOI":"10.1111\/dth.15763","article-title":"Therapeutic options for perifolliculitis capitis abscedens et suffodens: a review","volume":"35","author":"Wu","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaad.2021.03.076","article-title":"Risk factors for dissecting cellulitis of the scalp: a case-control study","volume":"86","author":"Tran","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/dth.12222","article-title":"Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients","volume":"28","author":"Sand","year":"2015","journal-title":"Dermatol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11926-013-0346-y","article-title":"Spondyloarthritis associated with acne conglobata, hidradenitis suppurativa and dissecting cellulitis of the scalp: a review with illustrative cases","volume":"15","author":"Lim","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"22692","DOI":"10.5070\/D3205022692","article-title":"Dissecting cellulitis (Perifolliculitis Capitis Abscedens et Suffodiens): a comprehensive review focusing on new treatments and findings of the last decade with commentary comparing the therapies and causes of dissecting cellulitis to hidradenitis suppura","volume":"20","author":"Scheinfeld","year":"2014","journal-title":"Dermatol Online J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e139932","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"JCI Insight"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/1346-8138.14998","article-title":"Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors: a case report and review of published cases","volume":"46","author":"Takahashi","year":"2019","journal-title":"J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archdermatol.2010.16","article-title":"3 cases of dissecting cellulitis of the scalp treated with Adalimumab: control of inflammation within residual structural disease","volume":"146","author":"Navarini","year":"2010","journal-title":"Arch Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergol Int"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","volume":"53","author":"Mogul","year":"2019"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of Baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e13646","DOI":"10.1111\/acel.13646","article-title":"TNF-\u03b1\/IFN-\u03b3 synergy amplifies senescence-associated inflammation and SARS-CoV-2 receptor expression via hyper-activated JAK\/STAT1","author":"Kandhaya\u2010Pillai","year":""},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2022-222335","article-title":"Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus","volume":"81","author":"D\u00f6rner","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00575-3","article-title":"Therapeutic drug monitoring in patients with suboptimal response to Adalimumab for Hidradenitis Suppurativa: a retrospective case series","volume":"22","author":"Abdalla","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref25","year":"2019"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/ced.14789","article-title":"Hidradenitis suppurativa with perifolliculitis capitis abscedens et suffodiens successfully treated with a human anti-tumour necrosis factor monoclonal antibody","volume":"46","author":"Minakawa","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1308\/rcsann.2020.7096","article-title":"Severe dissecting scalp cellulitis successfully treated with serial excisions in combination with anti-TNF therapy","volume":"103","author":"Spiers","year":"2021","journal-title":"Ann R Coll Surg Engl"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2147\/CCID.S301451","article-title":"Recalcitrant dissecting cellulitis of the scalp treated successfully with Adalimumab with hair regrowth: a case report","author":"Alsantali","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1111\/1346-8138.15945","article-title":"Perifolliculitis capitis abscedens et suffodiens with hidradenitis suppurativa and nodulocystic acne treated with adalimumab","volume":"48","author":"Kurokawa","year":"2021","journal-title":"J Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e1309","DOI":"10.1093\/milmed\/usz394","article-title":"A case report of tumor necrosis factor alpha inhibitors in an active duty service member with dissecting cellulitis of the scalp resistant to treatment","volume":"185","author":"Maxon","year":"2020","journal-title":"Mil Med"},{"key":"ref32","first-page":"255","article-title":"Perifolliculitis Capitis Abscedens et Suffodiens treated with anti-tumor necrosis factor-alpha - possible new treatment option","volume":"26","author":"Sjerobabski Masnec","year":"2018","journal-title":"Acta Dermatovenerol Croat"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjd.14269","article-title":"Dissecting cellulitis of the scalp treated with tumour necrosis factor-\u03b1 inhibitors: experience with two agents","volume":"174","author":"Mansouri","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref34","first-page":"102","article-title":"Refractory dissecting cellulitis of the scalp successfully controlled with Adalimumab","volume":"34","author":"Martin-Garc\u00eda","year":"2015","journal-title":"P R Health Sci J"},{"key":"ref35","first-page":"36","article-title":"Dissecting cellulitis of the scalp responding to intravenous tumor necrosis factor-alpha antagonist","volume":"5","author":"Navarini","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1365-2133.2008.08674.x","article-title":"Perifolliculitis capitis abscedens et suffodiens successfully controlled with infliximab","volume":"159","author":"Brandt","year":"2008","journal-title":"Br J Dermatol"},{"key":"ref37","first-page":"981","article-title":"Refractory dissecting cellulitis of the scalp treated with adalimumab","volume":"7","author":"Sukhatme","year":"2008","journal-title":"J Drugs Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1132574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T04:40:01Z","timestamp":1679978401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1132574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":37,"alternative-id":["10.3389\/fmed.2023.1132574"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1132574","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"article-number":"1132574"}}